Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(1):13-14; doi:10.1093/jnci/djj030
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Qualified Health Claim Rulings Leave Little Leeway for Label Language

Brian Vastag

The first 10% of the full text of this article appears below.

After 18 months of delays, the U.S. Food and Drug Administration announced in separate rulings that limited evidence supports labeling tomato products and green tea as reducing the risk of prostate cancer and prostate and breast cancers, respectively. However, the agency rejected much broader claims requested by the H.J. Heinz Company (for tomato products) and Fleminger Inc. (for green tea). It also rejected a request from American Longevity to allow the tomato extract lycopene to be labeled as a cancer risk reducer. The agency also concluded that there is "limited scientific evidence" to support the claim that calcium supplements . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?